Literature DB >> 9149223

Anti-inflammatory properties of unfractioned heparin in patients with highly active ulcerative colitis: a pilot study.

C Folwaczny, H Fricke, S Endres, G Hartmann, M Jochum, K Loeschke.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9149223

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  7 in total

1.  Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin.

Authors:  Hui-Fei Cui; Xue-Liang Jiang
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

Review 2.  Medical approaches and future options in chronic active ulcerative colitis.

Authors:  J T Siveke; C Folwaczny
Journal:  Int J Colorectal Dis       Date:  2004-01-15       Impact factor: 2.571

3.  Extensive arterial and venous thrombosis in a patient with ulcerative colitis--a case report.

Authors:  S Jain; P Bhatt; G K Muralikrishna; P Malhotra; S Kumari; S Varma
Journal:  MedGenMed       Date:  2005-04-26

4.  Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.

Authors:  I Dotan; A Hallak; N Arber; M Santo; A Alexandrowitz; Y Knaani; R Hershkoviz; E Brazowski; Z Halpern
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

Review 5.  Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.

Authors:  Nilesh Chande; Yongjun Wang; John Wd McDonald; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2015-08-05

6.  Different therapy for different types of ulcerative colitis in China.

Authors:  Xue-Liang Jiang; Hui-Fei Cui
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

Review 7.  The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development.

Authors:  Essam Elsayed; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.